pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·Jul 17·1 min read
save

Zealand Pharma appoints former Lilly executive as US marketing head

Jul 17, 2026·read at Endpoints ↗Neutral

Silvia Luque announced on LinkedIn that she will lead US marketing for Zealand Pharma. The appointment follows a 13-year tenure at Eli Lilly, where she held several roles in the company's obesity franchise.

During her time at Lilly, Luque gained experience in product strategy, launch planning and cross-functional leadership, positioning her to drive Zealand's US commercial efforts for its pipeline.

In a separate move, biotech Bexorg named a new chief scientific officer from Biohaven, underscoring the company's focus on expanding its scientific leadership.

source

This writeup was produced by pharmadog from original reporting by Endpoints.

Original headline: “Zealand Pharma gets its US marketing leader from Lilly; Bexorg turns to Biohaven for CSO hire”

read at Endpoints ↗
95 words · retrieved Jul 17
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
LILLY4ZEALAND PHARMA3ELI LILLY CO2
drugs
Obesity2
topics
Obesity2

related stories

  • 3d agoFDA review docs spark Revolution sell-off; Zealand diabetes data underwhelm analystsBioPharma Dive
  • 5d agoZealand, Roche topline a Phase 2 study for amylin drug, though Lilly remains an obstacleEndpoints
  • 5d agoDespite Zealand asset’s ‘intriguing’ weight loss, analysts underwhelmed by blood sugar numbersBioSpace
  • 5d agoZealand, Roche’s ‘intriguing’ weight loss for amylin drug soured by blood sugar dataFierce Biotech
  • Oct 2STAT+: Pharmalittle: We’re reading about the 340B drug pilot program, an obesity drug disappointment, and moreSTAT